a wholly-owned subsidiary of FSD Pharma Inc.
In Pursuit of Total Brain Health
Lucid Psycheceuticals is a psychedelics-inspired biotech company
Our therapeutics are inspired by the action that psychedelics can have on preventing and possibly reversing the neurodegeneration that leads to brain illnesses. Our team is composed of highly specialized science experts focused on providing leading edge small molecule therapeutics for total brain health.
Mental Health
Disorders
Lucid's team has shortlisted Lucid-201, a known molecule with clinical proof of efficacy in major depressive disorder (MDD) and related psychiatric conditions.
Neurodegenerative
Disorders
Lucid completed the acquisition of exclusive world-wide license to new chemical entities (NCEs), associated patents and preclinical efficacy data from University Health Network (UHN, Toronto, Canada) in May 2021.
Investors
Lucid Psycheceuticals is a wholly-owned subsidiary of FSD Pharma, Inc. (HUGE), a publicly-traded company.